Telix a standout diagnostic and therapeutic radiopharmaceutical play
Telix Pharmaceuticals (US) Inc, a subsidiary of Telix Pharmaceuticals Limited (ASX: TLX) announced on Friday that it has entered into a commercial distribution agreement with Boca Raton-based Pharmalogic Holdings Corp. (Pharmalogic) to provide nuclear pharmacy and logistics services to support Telix’s prostate cancer imaging product TLX591-CDx (68GaPSMA-11), a radiopharmaceutical for the imaging of metastatic prostate cancer.
This was an important development for Telix, and while its shares were up slightly during the day it could be argued that the significance of the agreement was missed by the broader market.
Under the agreement, Pharmalogic will prepare and deliver patient-specific unit-doses of TLX591-CDx, for the US market through its network of 27 nuclear medicine pharmacies.
Pharmalogic’s nuclear medicine pharmacy network services predominantly regional and rural areas in the Midwest and Northeast regions of the United States.
Pharmalogic president and chief executive Steven Chilinski is already looking towards commercialisation, and he said, “The collaborative partnership between Telix and Pharmalogic is being highlighted by the planned launch of this highly anticipated prostate imaging agent, ensuring that this important drug is available to our customers and patients, and furthering our mission to advance the development and commercialisation of new, game-changing diagnostic and therapeutic radiopharmaceuticals.”
Blue Ocean Equities highlights five near-term re-rating events
By way of background, TLX591-CDx (kit for the preparation of 68Ga-PSMA-11) is a proprietary formulation of PSMAHBED-CC (PSMA-11), a novel small molecule agent targeting prostate-specific membrane antigen (PSMA), originally developed by the Heidelberg group of the Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ).
The ‘cold kit’ format of TLX591-CDx enables rapid radio-labelling at room temperature with high radio-chemical purity and production consistency, ideally suited for the radio-pharmacy setting.
TLX591-CDx (kit) is branded and trademarked in the US as illumet.
Currently, US TLX591-CDx is available for investigational use only as part of an FDA Investigational New Drug (IND) application, but it is already generating revenues for Telix while being used in this capacity.
While TLX591-CDx is not presently an FDA approved agent, its approval is one of a number of value accretive near-term catalysts identified by Blue Ocean Equities analyst Michael Gerges who said last week, ‘’Near-term material re-rating events include: (1) US & EU marketing approval for TLX591-CDx (3Q/4Q20); (2) Commercial launch of illumet (1Q21); (2) FDA ‘green light’ on commencement of PROSTACT Ph3 trial for TLX591 (4Q20); (4) first patient dosing of PROSTACT Ph3 trial in Australia (4Q20); and (5) completion of enrolment for ZIRCON Ph3 trial (4Q20).’’
Gerges has just updated his price target from $1.70 to $2.10, implying share price upside of 50% relative to Monday’s closing price.
The broker highlighted that Telix was well funded with negligible debt and a cash balance of $34.5 million.
This along with a research and development credit of $11 million which should boost the coffers in the second half of 2020 will provide the company with ample funding to progress the initiatives that could lead to a very significant share price rerating.
The other factor working in Telix’s favour is that it is already generating revenues, and after nearly doubling to $6 million in 2020, Gerges expects income to increase more than six-fold in 2021 with forecast revenues of $37.6 million.
The broker is projecting Telix to deliver its maiden net profit of $21.6 million in fiscal 2022.
While operational milestones are likely to be the key catalysts over the next six months, investors who target the limited clutch of smaller players with material cash flows and medium-term earnings predictability are likely to focus on Telix as revenues accelerate in 2021 ahead of its maiden profit.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.